Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Reconstitute at 0.5 mg/mL in sterile PBS.
The 20S immunoproteasome is a specialized form of the proteasome complex that plays a crucial role in the immune system by processing intracellular proteins into peptides for presentation on major histocompatibility complex (MHC) class I molecules. This process is essential for the recognition of infected or malignant cells by cytotoxic T lymphocytes. The immunoproteasome is composed of unique catalytic subunits, including LMP2 (PSMB9), LMP7 (PSMB8), and MECL-1 (PSMB10), which replace their constitutive counterparts in the standard proteasome. These subunits enhance the generation of peptides that are optimal for MHC class I binding. The formation of the immunoproteasome is induced by inflammatory cytokines such as interferon-gamma (IFN-gamma), which are released during immune responses to infections or tumors. Beyond its role in antigen presentation, the immunoproteasome also contributes to the regulation of cytokine production and the maintenance of protein homeostasis under stress conditions. Dysregulation or mutations in the components of the immunoproteasome have been implicated in various autoimmune diseases, such as lupus and rheumatoid arthritis, as well as in certain cancers. Understanding the function and regulation of the 20S immunoproteasome is important for developing therapeutic strategies aimed at modulating immune responses, enhancing cancer immunotherapy, and treating autoimmune disorders.
仅用于科研。不用于诊断过程。未经明确授权不得转售。